Stromal Compartment as a Survival Prognostic Factor in Advanced Ovarian Carcinoma

2010 ◽  
Vol 20 (1) ◽  
pp. 28-33 ◽  
Author(s):  
Alexandre Labiche ◽  
Natacha Heutte ◽  
Paulette Herlin ◽  
Jacques Chasle ◽  
Pascal Gauduchon ◽  
...  
Keyword(s):  
Prognostic Factor ◽  
Ovarian Carcinoma ◽  
Stromal Compartment ◽  
Advanced Ovarian Carcinoma

DNA Index by Flow Cytometric Analysis: An Additional Prognostic Factor in Advanced Ovarian Carcinoma without Residual Disease after Primary Operation

1996 ◽  
Vol 62 (2) ◽  
pp. 208-212 ◽  
Author(s):  
Gerardo Zanetta ◽  
Gary L. Keeney ◽  
Stephen S. Cha ◽  
Harry S. Wieand ◽  
Jerry A. Katzmann ◽  
...  
Keyword(s):  
Prognostic Factor ◽  
Ovarian Carcinoma ◽  
Residual Disease ◽  
Flow Cytometric Analysis ◽  
Dna Index ◽  
Primary Operation ◽  
Advanced Ovarian Carcinoma ◽  
Flow Cytometric

CA125 nadir as a prognostic factor in advanced ovarian carcinoma: A retrospective study of 84 patients achieving clinical CR

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 5060-5060 ◽  
Author(s):  
H. Tanabe ◽  
N. Katsumata ◽  
K. Matsumoto ◽  
S. Nishio ◽  
Y. Kato ◽  
...  
Keyword(s):  
Multivariate Analysis ◽  
Prognostic Factor ◽  
Ovarian Carcinoma ◽  
Residual Tumor ◽  
Initial Therapy ◽  
Hazard Ratio ◽  
Tumor Diameter ◽  
First Line ◽  
Advanced Ovarian Carcinoma ◽  
Line Chemotherapy

5060 Background: There have been few reports of the relationship between CA125 nadir and the prognosis in patients with advanced ovarian carcinoma (AOC) who achieve a complete clinical response by multivariate analysis. Methods: CA125 nadir and the prognosis after the initial therapy (debulking surgery + first line chemotherapy) were retrospectively investigated in patients (pts) who had AOC meeting the criteria below and received therapy at National Cancer Center Hospital, between 1998 and 2004. The eligibility criteria were: 1) histological diagnosis of mullerian carcinoma, 2) FIGO stages III and IV, 3) a combination of platinum and taxane was administered as the first line chemotherapy, and 4) achieved clinically defined complete response (CR) after the initial therapy (ie, no cancer-related symptoms; normal physical examination, computed tomography scan of the abdomen/pelvis and chest x-ray). The possibility of CA125 nadir being a prognostic factor was investigated in pts who met these criteria by multivariate analysis (age (<50 years or 50 years≤), stage (III or IV), histological type (serous adenocarcinoma (serous) or non-serous), residual tumor diameter (<2 cm or 2 cm≤) and CA125 nadir (<10 U/ml or 10 U/ml≤)) using the Cox regression model. Results: There were 84 pts with a median age of 55.5 years (26–74). The stage was III in 59 pts and IV in 25 pts, the histological type was serous in 71 pts and non-serous in 13pts, and the residual tumor diameter was <2 cm in 72 pts and >2 cm in 12 pts and the median of CA125 before the initial therapy was 535 U/ml (13–28190), the CA125 nadir was <10 U/ml in 54 pts and 10 U/ml≤ in 30 pts, respectively. Regarding the prognosis, the median progression free survival (PFS) was 19 months (6–82), and the median overall survival (OS) was 36.5 months (10–82). By multivariate analysis, the CA125 nadir was significantly associated with the prognosis (hazard ratio of PFS was 0.39 (95% CI, 0.21–0.71), hazard ratio of OS was 0.28 (95% CI, 0.11–0.72)). Conclusion: CA125 nadir is a prognostic factor in patients with AOC who achieved clinically defined CR after the initial therapy, when the cut-off value was set to 10 U/ml. CA125 nadir may be an important factor for identifying pts for whom maintenance chemotherapy is effective. [Table: see text]

The treatment of advanced ovarian carcinoma (I): Clinical variables associated with prognosis

1988 ◽  
Vol 30 (3) ◽  
pp. 347-358 ◽  
Author(s):  
A.Peter M. Heintz ◽  
Allan T. Van Oosterom ◽  
J.Baptist M.C. Trimbos ◽  
Aart Schaberg ◽  
Edo A. Van Der Velde ◽  
...  
Keyword(s):  
Ovarian Carcinoma ◽  
Clinical Variables ◽  
Advanced Ovarian Carcinoma
Sign in / Sign up

Export Citation Format

Share Document